Apogee Therapeutics, Inc.
APGEDelisted Sep 3, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001974640
Apogee Therapeutics, Inc. was delisted on Sep 3, 2026; its insiders filed their last Form 4 on Sep 3, 2026; 288 institutions reported holding it in 13F filings for Q2 2026, worth $8.93B in total; Soros Fund Management was the only superinvestor holding it.
Q1 2024 vs. Q4 2023
How the institutions holding Apogee Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 85 | 139 | +54 |
| Shares | 41.8M | 52.9M | +11.1M (+26.7%) |
| Value | $1.16B | $3.52B | +$2.35B (+202.2%) |
New holders (62)
Institutions that held Apogee Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (8)
Institutions that held Apogee Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Vivo Capital, LLC | 400,000 | $11.2M |
| Frazier Life Sciences Management, L.P. | 400,000 | $11.2M |
| Holocene Advisors, LP | 101,202 | $2.83M |
| Sphera Funds Management Ltd. | 30,000 | $838.2K |
| Hudson Bay Capital Management LP | 20,000 | $558.8K |
| Jump Financial, LLC | 18,344 | $512.5K |
| Caxton Corp | 7,353 | $205.4K |
| Glassman Wealth Services | 12 | $335 |